Atria Investments Inc Purchases 35,788 Shares of Boston Scientific Corporation $BSX

Atria Investments Inc boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 85.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,476 shares of the medical equipment provider’s stock after purchasing an additional 35,788 shares during the period. Atria Investments Inc’s holdings in Boston Scientific were worth $7,564,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. State Street Corp increased its holdings in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC raised its position in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific in the 2nd quarter worth $2,089,937,000. Finally, Invesco Ltd. grew its position in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Up 0.8%

Shares of NYSE:BSX opened at $74.72 on Friday. The business’s 50 day moving average price is $90.93 and its 200-day moving average price is $97.69. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50. The firm has a market capitalization of $110.76 billion, a price-to-earnings ratio of 38.51, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the firm posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent research reports. Oppenheimer dropped their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. National Bank Financial set a $115.00 price target on Boston Scientific in a research report on Monday, February 2nd. Wells Fargo & Company dropped their price objective on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Evercore cut their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $109.43.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.